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Abstract
Background: With over 20 million formalin-fixed, paraffin-embedded (FFPE) tissue samples archived each year in
the United States alone, archival tissues remain a vast and under-utilized resource in the genomic study of cancer.
Technologies have recently been introduced for whole-transcriptome amplification and microarray analysis of
degraded mRNA fragments from FFPE samples, and studies of these platforms have only recently begun to enter
the published literature.
Results: The Emerging Technologies for Translational Bioinformatics symposium on gene expression profiling for
archival tissues featured presentations of two large-scale FFPE expression profiling studies (each involving over
1,000 samples), overviews of several smaller studies, and representatives from three leading companies in the field
(Illumina, Affymetrix, and NuGEN). The meeting highlighted challenges in the analysis of expression data from
archival tissues and strategies being developed to overcome them. In particular, speakers reported higher rates of
clinical sample failure (from 10% to 70%) than are typical for fresh-frozen tissues, as well as more frequent probe
failure for individual samples. The symposium program is available at http://www.hsph.harvard.edu/ffpe.
Conclusions: Multiple solutions now exist for whole-genome expression profiling of FFPE tissues, including both
microarray- and sequencing-based platforms. Several studies have reported their successful application, but
substantial challenges and risks still exist. Symposium speakers presented novel methodology for analysis of FFPE
expression data and suggestions for improving data recovery and quality assessment in pre-analytical stages.
Research presentations emphasized the need for careful study design, including the use of pilot studies, replication,
and randomization of samples among batches, as well as careful attention to data quality control. Regardless of
any limitations in quantitave transcriptomics for FFPE tissues, they are often the only biospecimens available for
large patient populations with long-term history and clinical follow-up. Current challenges can be expected to
remain as RNA sequencing matures, and they will thus motivate ongoing research efforts into noise reduction and
identification of robust, translationally relevant biological signals in expression data from FFPE tissues.
Text
The Emerging Technologies for Translational Bioinfor-
matics symposium on gene expression profiling for
archival tissues was held on August 5, 2011, in response
to interest from numerous researchers in the planning
stages of large-scale expression profiling studies using
clinical FFPE tissues. While a number of smaller-scale
studies have demonstrated technical feasibility of FFPE
expression profiling, it remains a novel technology with
great potential but still-unknown risks and challenges.
This symposium brought together some of the most
experienced researchers in the field, to share experiences
and provide an early look at the particular risks and
issues involved.
The symposium comprised two keynote presentations
by Dr. Jeannette Eckel-Passow and Dr. Mickey Williams,
each discussing their experiences with large, published
studies featuring FFPE gene expression data. Dr. Eckel-
Passow is a statistician for the North Central Cancer
Treatment Group-led N9831 intergroup clinical trial at
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1,500 FFPE HER-2 positive breast tumor specimens
from 400 centers in the largest FFPE expression profil-
ing study yet undertaken. Dr. Williams is one of the
longest-standing researchers in archival tissue gene
expression profiling, having performed several of the
earliest RT-PCR studies, and he discussed assay develop-
ment specifically for clinical applications using expres-
sion profiling of FFPE tissues. Other presentations
featured as-yet-unpublished studies from the University
of Queensland (by Dr. Peter Simpson), Harvard School
of Public Health (by Dr. Levi Waldron), and Dana-Far-
ber Cancer Institute (by Dr. John Quackenbush). These
investigations featured novel methods development for
the analysis of FFPE expression profiles, which represent
au n i q u er e s o u r c eb u tw h i c hr equire additional plan-
ning, quality control, and care in interpretation relative
to studies of frozen tissues. The symposium provided an
early look at the challenges that will become increas-
ingly widespread as expression profiling of FFPE tissues
enters the mainstream, and it provided practical guide-
lines for the planning and analysis of such experiments.
Planning of large-scale FFPE expression profiling studies
Planners of FFPE expression studies must select an ana-
lysis platform in the face of limited and sometimes con-
tradictory pieces of evidence. Considerations in these
p r e - s t u d ys t a g e sw e r ed i s c u s s e db yap a n e lo ft h r e e
investigators currently completing such designs for
FFPE profiling, Dr. Lorelei Mucci (Harvard School of
Public Health), Dr. Michael Birrer (Massachusetts Gen-
eral Hospital), and Dr. Matthew Freedman (Dana-Farber
Cancer Institute). Among the current alternatives avail-
able for whole-genome profiling are Illumina’sW G -
DASL
® assay or NuGEN/Affymetrix for amplification/
hybridization, or profiling of a limited gene panel by
Nanostring nCounter technology. Since the particulars
of sample fixation and storage have lasting influence on
expression profiling, all panel members undertook tar-
geted pilot projects before moving ahead on a large
scale. A central theme in this discussion was the deci-
sion whether to optimize accuracy by assaying only a
panel of selected candidate genes, or to take a whole-
genome approach with potentially lower accuracy. The
development of methods for selecting a candidate gene
panel was identified as a pressing research need for the
bioinformatics and biostatistics communities. The
experimental design phase of planning was discussed by
Dr. Eckel-Passow, who emphasized attention to rando-
mization, to ensure balance of any variables of interest
across the order of RNA extraction and across 96-well
PCR plates, as well as the use of positive control sam-
ples on each plate, and within-plate and between-plate
replication. These steps enabled post-hoc identification
of problematic batches which could then be repeated,
and ensured that batch-specific variations were not con-
founded with the outcome of interest.
Analysis of FFPE expression data
Microarray data from FFPE tissues show overall greater
amounts of noise and technical effects than would be
expected from fresh-frozen tissues, a message presented
by all four morning speakers. In the analysis of expres-
sion data from 1,500 clinical trial FFPE specimens, Dr.
Eckel-Passow demonstrated how visualization of raw
data, through box plots sorted by plate and extraction
order, enabled post-hoc identification of issues affecting
data quality at different parts of the experiment, so that
the affected samples could be removed, re-assayed, and
otherwise corrected for in downstream analysis. She pre-
sented a novel “stress” metric for quality control, which
quantified the extent of changes to raw expression
values during normalization and identified samples with
unusually compressed or skewed distributions of raw
intensity measurements. Dr. Levi Waldron noted an
approximately 20% rate of sample failure in a study of
1,003 colorectal cancer specimens from long-term
health studies, ands h o w e dt h a ts t r i c tq u a l i t yc o n t r o l
improved reproducibility in the ranking of differentially
expressed genes and of probe-level measurements
between replicates. Two other speakers presented smal-
ler-scale Illumina DASL
® technical studies, highlighting
the risks still present from assay and sample variability,
and the need for pilot studies using samples from the
actual study population. Dr. Peter Simpson from the
University of Queensland, Australia, presented two pub-
lished breast cancer microarray studies which showed
promising results [1,2], but more recently experienced
70% sample failure rate in a 96-sample breast cancer
experiment. These sample failures were not predicted
from sample age, qPCR of housekeeping genes, or RNA
quality or quantity. Dr. Simpson also observed that in
technical replicate measurements of the same sample by
Illumina WG-DASL
®,s o m ep r o b e sw e r ed e t e c t e di n
one replicate and not the other. Dr. Mickey Williams
pointed out during subsequent questions that mRNA
transcripts are amplified from very low levels for quanti-
tation in FFPE tissues, to the extent that a single intact
transcript segment can be measured, which could result
in noticeable random variations between technical
replicates.
To close the morning, Dr. John Quackenbush of the
Dana-Farber Cancer Institute reported on a pilot study
of Illumina DASL
® for the DRIVE U19 breast cancer
project. In this pilot study, sample expression profiles
c l u s t e r e dm o r es t r o n g l yb yR N Ai n p u tc o n c e n t r a t i o n
than by Estrogen Receptor status, and the decision was
made to move from whole-transcriptome analysis to an
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This presentation also provided a glimpse into the
future of RNA-seq, which was assessed in a pilot study
of seven FFPE bladder cancer samples. The analysis pro-
c e s sw a ss i m i l a rt oR N A - s e qf o rf r e s h - f r o z e ns a m p l e s
without the need to fragment RNA, using DSN normali-
zation. This process reduces ribosomal RNA abundance,
necessary since poly-A selection cannot be performed
on FFPE tissues, and the resulting expression profiles
showed promising separation of proliferative and non-
proliferative tumor types.
State of the technology, by industry representatives
Industry representatives from Illumina, NuGEN, and
Affymetrix summarized their solutions for expression
profiling of FFPE samples by microarray and RNA-seq,
as well as for methylome profiling.
Illumina provides the WG-DASL
® H T - 1 2v 4s y s t e m
for cDNA labeling, sequence-specific amplification, and
hybridization. This system differs from other approaches
in that cDNA amplification is limited to oligo-targeted
sequences, for specificity of detection. Illumina has
recently developed two technologies enabling RNA-seq
on FFPE tissues as well, and additionally offers the Infi-
nium HumanMethylation450 BeadChip for whole-gen-
ome methylations study of FFPE tissues.
NuGEN discussed their Ovation
® FFPE RNA Ampli-
fication System v2, which can be used to amplify pico-
gram quantities of starting RNA, using a proprietary
SPIA process for linear DNA amplification at constant
temperature. The amplified cDNA product can be used
in combination with any microarray platform or with
RNA-seq, and an example was shown of equivalence in
results obtained from RNA-seq and microarray with
common NuGEN preparation. This process was
recently revised to increase sensitivity, and results were
shown that demonstrated increased detection of biolo-
gically relevant genes as compared to previous
versions.
An Affymetrix representative indicated that their
microarrays, including the familiar Human Genome
U133 Plus 2 and newer exon arrays, can be employed
directly with RNA from FFPE tissues. These are nor-
mally used in combination with NuGEN Ovation
® sam-
ple preparation, and successful examples of such
combinations were presented by both Affymetrix and
NuGEN. The Affymetrix miRNA array and some arrays
used for GWAS and copy number can also be used for
FFPE samples.
When asked about future trends in the technology,
industry speakers noted a trend towards next-generation
sequencing, and toward integrating genetic, epigenetic
and expression analyses of FFPE samples.
“De-Risking” FFPE expression profiling for clinical assay
development
In the clinical assay development, it is critically impor-
tant to avoid mistakes in diagnosis. To this end it may
be necessary to allow an outcome of “indeterminate” in
some cases. Afternoon keynote speaker Mickey Wil-
liams, from the Patient Characterization Center and
Clinical Assay Development Center, SAIC-Frederick,
Inc., presented a case study in the development of an
expression-based diagnostic assay for diffuse large B-cell
lymphoma from FFPE tissues, using NuGEN sample
preparation and Affymetrix microarrays [3]. Assay devel-
opment required fresh-frozen tissues to establish a
model to sub-classify diffuse large B-cell lymphomas
into the prognostic subgroups germinal center B-cell
(GCB) and activated B-cell (ABC), which was then
extended to FFPE tissue samples. FFPE tissues provided
lower-quality data, but remained valuable for accurate
disease classification. With the central importance of
accuracy in clinical assay development in mind, Dr. Wil-
liams outlined steps to “de-risk” expression profiling
from FFPE tissues:
￿ RNA concentration and Bioanalyzer RNA Integrity
Number (RIN) were often not sufficiently predictive of
true expression data quality.
￿ qRT-PCR of a housekeeping gene proved very infor-
mative and was usable for quality assurance of each
sample by defining an acceptable range of Ct scores.
Low linear amplification yield was indicative of poor
sample quality.
￿ Ambient moisture during tissue storage or handling
can be unavoidable, but was consistently observed to
degrade subsequent expression assays.
￿ Developers of clinical assays should demand an adja-
cent section for H & E staining, to confirm diagnosis
and assess cellularity which may impact gene expression
measurements.
Summary
FFPE tissues represent an irreplaceable and under-uti-
lized library of the trancriptomes of large patient popu-
lations with long-term clinical follow-up, and such
samples are utilized for virtually all routine pathology
tests. However, expression data from such tissues typi-
cally include more noise than do data from fresh-frozen
tissues, a cost of their closeness to the clinic and widely
varied storage and handling processes. FFPE expression
data are more prone to sample bias and failure, and
they can vary widely even among different samples of
the same tissue type. Symposium presenters suggested
steps to successfully overcome these challenges, includ-
ing the use of pilot studies, positive control samples,
replication, balanced randomization of samples to
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effects and low-quality samples during data analysis.
RNA-seq will likely soon be a viable alternative to
microarray hybridization, but sample characteristics
introduced by the FFPE preservation process will
remain. Numerous FFPE studies of unprecedented scale
in the microarray literature are in their planning and
execution stages, and the field can expect to continue
exploring the analysis and interpretation of these archi-
val tissue gene expression data.
Note
A symposium held on August 5, 2011 at the Dana-Far-
ber Cancer Institute
Abbreviations
Ct: Cycle Threshold; qRT-PCR: Quantitative Real-time PCR; RIN: RNA Integrity
Number; FFPE: Formalin-Fixed Paraffin-Embedded; H & E: Hematoxylin and
Eosin Stain; DSN: duplex-specific nuclease; WG-DASL: Whole-Genome cDNA-
mediated Annealing Selection, extension, and Ligation.
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